Pharmaceutical

WuXi debates sale of pharma operations as BIOSECURE Act advances

WuXi is considering the sale of some US and European operations to mitigate the impact of upcoming restrictions.

Oct 6, 2024 - 04:00
WuXi debates sale of pharma operations as BIOSECURE Act advances
WuXi is considering the sale of some US and European operations to mitigate the impact of upcoming restrictions.
Read the original article

Tags:

Previous Article

Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m

Next Article

The benefits of using a nimble platform from phase to phase

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Acelyrin, a rare IPO success, stumbles in its first big test

STAT+: Acelyrin, a rare IPO success, stumbles in its fi...

Sep 12, 2023

SCOPE: FDA facilitates AI and ML use for clinical trials and drug development

SCOPE: FDA facilitates AI and ML use for clinical trial...

Feb 14, 2024

Which drugs are most likely to be approved in Bipolar I...

Mar 28, 2024